A novel series of benzimidazoles was identified and optimized, leading to the discovery of potent and selective antagonists of the human melanocortin-4 receptor. In addition, compound 5i was shown to cross the blood-brain barrier after intravenous dosing in rats. (c) 2007 Elsevier Ltd. All rights reserved.
Substituted benzimidazole derivatives as melanocortin 4 receptor antagonists
申请人:Santhera Pharmaceuticals (Schweiz) AG
公开号:EP2439197A1
公开(公告)日:2012-04-11
The present invention relates to substituted benzimidazole derivatives as melanocortin-4 receptor (MC-4R) modulators.